Drug facts
MoleculeDalbavancin (Dalvance)
Generics already compete: 5 makers on the market. 5 A-rated products from 5 makers substitute at the counter.
Dalvance was first approved by the FDA on 05/23/2014 under NDA 021883; the application holder is Abbvie Inc.
Holder Abbvie IncApplication NDA 021883Approved 05/23/2014
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
570days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved05/23/2014
Last patent05/23/2028
201520182021202420272030
- Latest patent
- 05/23/2028Dalvance Orange Book
02Competition
- Generics
- 5 generic makers Orange Book
- First generic approved
- 10/23/2025 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Dalbavancin profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 021883 Orange Book
- First approved
- 05/23/2014 Orange Book
- Dosage forms
- powder
- Routes
- intravenous
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.